Immuno-Oncology | Specialty

Dr. Link on Algenpantucel-L for Pancreatic Cancer

July 15th 2013

Charles J. Link, Jr, MD, from the Cancer Center of Iowa and NewLink Genetics, discusses the phase II trial of algenpantucel-L for pancreatic cancer.

Novel Two-Step Immunotherapy Shows Promise in Early-Stage Ovarian Cancer Study

July 9th 2013

A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.

Dr. Bruce Roth on Curing Cancer With Immunotherapies

July 9th 2013

Bruce Roth, MD, from the Siteman Cancer Center, Washington University School of Medicine, discusses the optimism for a cure with immunotherapies.

Dr. Weber Explores Nivolumab in Advanced Melanoma

June 21st 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

Dr. Shore on Immunotherapies for Prostate Cancer

June 20th 2013

Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, gives an overview of the development of immunotherapies for patients with prostate cancer.

Dr. Wolchok on Concurrent Ipilimumab and Nivolumab

June 19th 2013

Jedd D. Wolchok, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Dr. Saenger on Combining Targeted and Immune Agents

June 12th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

The Future of Melanoma Treatment

June 6th 2013

Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.

Dr. Herbst on the Emergence of Immunotherapy in Cancer

June 5th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, describes the emergence of immunotherapy as a treatment in multiple types of cancer that was highlighted at the 2013 ASCO Annual Meeting.

GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma

June 2nd 2013

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

Nivolumab Delivers Enduring Benefits in Advanced Melanoma

June 2nd 2013

Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.

Dr. Sznol Describes Nivolumab in Advanced Melanoma

June 2nd 2013

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

ASCO Highlights Put Variety in Spotlight

June 1st 2013

New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.

Translating Combination Radiotherapy/Immunotherapy From Dogs to Humans With Advanced Melanoma or Sarcoma

May 29th 2013

Arta Monjazeb, MD, and Michael Kent, DVM, from the UC Davis Comprehensive Cancer Center, describe an early phase trial exploring the potential of translating successful treatment from dogs to humans with advanced melanoma or sarcoma.

Beyond Provenge: The Next Steps With Immunotherapy in Prostate Cancer

May 17th 2013

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, provides an overview of the most promising immunotherapeutic follow-ups to sipuleucel-T in prostate cancer.

Combining Ipilimumab and Nivolumab Shows Promise in Advanced Melanoma

May 16th 2013

Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.

Early Results Robust for New PD-L1 Immunotherapy Agent

May 15th 2013

An antibody that targets PD-L1 to unleash the body's immune system has demonstrated a 21% response rate in a phase I study of patients with multiple solid tumors, setting the stage for an advance in immunotherapy with broad implications for treatment.

Dr. Petrylak Describes the Investigation of PROSTVAC

May 3rd 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Dr. Tanyi Describes a Novel Two-Step Immunotherapy

May 2nd 2013

Janos L. Tanyi, MD, PhD, from the University of Pennsylvania, discusses two phase I studies that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Use of Sipuleucel-T Refined

April 30th 2013

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.